Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
- August 14th, 2023
- 417 views
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' projected revenue of $95.45 million.
$SCYX was trading at $2.94 in after-hours, up $0.14 (+5.00%).
In contrast, Nogin, Inc. (Nasdaq: NOGN), a company in the financial sector, reported a Q2 2023 loss of $(1.13) per share, missing the consensus estimate loss of $(0.90) per share. Moreover, the company generated quarterly sales of $12.70 million, falling short of analysts' expected revenue of $14.94 million.
For the full year 2023, Nogin anticipates net revenue to range between $50 million and $55 million, attributed to the decision to exit low-margin relationships, in comparison to the consensus estimate of $79.24 million in revenue for the period.
In after-hours, $NOGN was trading at $0.80, down $0.18 (-17.95%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login